The rise of more transparent, "Cost Plus" pharmacy models is stirring debate within the pharmaceutical space as smaller players put pressure on the large PBMs.

After hinting COVID-19 drug Pemgarda might not work against new strains, the FDA announced the medication is effective against KP.3.1.1, the dominant variant. 

Johnson & Johnson will discontinue upfront 340B drug rebates for certain hospitals, raising concerns among healthcare providers and advocacy groups. The proposed policy, set to take effect Oct. 15, would prevent certain hospitals from accessing 340B discounts for Stelara, used to treat plaque psoriasis, psoriatic arthritis and other conditions; and Xarelto, a blood thinner. 

A recent study highlighted the use of MRIs in reducing overdiagnosis in prostate cancer screening. 

A recent study suggests that semaglutide, typically used for Type 2 diabetes, may significantly reduce the risk of opioid overdoses in patients with opioid use disorder, according to research published Sept. 25 by JAMA Network.

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades, Medscape reported Sept. 20. 

Pfizer has announced the withdrawal of all lots of Oxbryta, its drug for sickle cell disease, amid concerns about increased complications and fatal events. 

Large companies can save millions of dollars by addressing one common misconception about health insurance plans, according to billionaire entrepreneur Mark Cuban. 

The FDA is reassessing the approval of immune checkpoint inhibitors for treating advanced HER2-negative gastric adenocarcinoma, questioning their broad application regardless of patients' PD-L1 expression levels. 

A recent study from Harvard Medical School introduced TxGNN, an innovative AI tool designed to identify potential drug candidates for over 17,000 rare and neglected diseases. 

Sen. Bernie Sanders highlighted a potential shift in the pricing of Ozempic during a Senate Health, Education, Labor and Pensions Committee hearing Sept. 24, during which three major pharmacy benefit managers said they would increase coverage if Novo Nordisk lowered the drug's list price. 

In the first quarter of 2024, the U.S. recorded a spike in drug shortages and among GoodRx's list of the top 20 most common medications, half are in shortage. 

Here are eight new drug shortages to know, according to databases compiled by the FDA and the American Society of Health-System Pharmacists: 

CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027. 

GLP-1 manufacturers are now offering significant discounts to entice payers and employers to cover their popular medications, The Wall Street Journal reported Sept. 20.

The FDA approved FluMist, a nasal spray flu vaccine for self-administration, making it the first flu vaccine of its kind available for at home use. 

A phase 3 study has shown that tolebrutinib, a drug being tested in treating non-relapsing secondary progressive multiple sclerosis, slowed the progression of disability in patients. 

Drugmakers will discontinue the sales of a controversial class of fentanyl-based painkillers by the end of September, the FDA confirmed Sept. 16. 

Bionpharma is recalling a batch of pneumonia drug Atovaquone Oral Suspension after it was found to be contaminated with Cohnella bacteria. 

Becker's asked chief pharmacy officers from hospitals and health systems across the U.S. to share the next steps in their technological journey.